<!DOCTYPE html>
<html lang="en">
<head>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>Lesson 2: Advanced Profiling: Lab Synthesis & Bio-Marker Integration</title>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
 <style>
/* ===========================================
 ACCREDIPRO GOLD STANDARD - UNIFIED LESSON CSS v5.0
 School-Quality ‚Ä¢ ASI Certified ‚Ä¢ Premium UX
 =========================================== */

/* Reset & Base */
* {
 box-sizing: border-box;
 margin: 0;
 padding: 0;
}

body {
 font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
 line-height: 1.8;
 color: #1f2937;
 background: #ffffff;
 font-size: 17px;
}

/* MAIN WRAPPER */
.lesson-wrapper {
 max-width: 1200px;
 margin: 0 auto;
 padding: 40px 20px;
}

/* HEADER CARD - Premium Gradient */
.module-header-card {
 background: linear-gradient(135deg, #722F37 0%, #722F37 50%, #5a252b 100%);
 padding: 48px 40px;
 margin-bottom: 40px;
 border-radius: 24px;
 box-shadow: 0 20px 60px -15px rgba(114, 47, 55, 0.4);
 border: none;
 text-align: center;
 position: relative;
 overflow: hidden;
}

.module-header-card::before {
 content: '';
 position: absolute;
 top: -50%;
 left: -50%;
 width: 200%;
 height: 200%;
 background: radial-gradient(circle, rgba(255, 255, 255, 0.05) 0%, transparent 70%);
 pointer-events: none;
}

.module-label {
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 3px;
 color: rgba(255, 255, 255, 0.8);
 margin-bottom: 12px;
 font-weight: 600;
 display: block;
}

.lesson-title {
 font-size: 38px;
 color: #ffffff;
 font-weight: 800;
 margin: 0 0 20px 0;
 line-height: 1.15;
 text-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
}

/* META BADGES */
.lesson-meta {
 display: flex;
 justify-content: center;
 gap: 12px;
 flex-wrap: wrap;
}

.meta-badge {
 background: rgba(255, 255, 255, 0.15);
 color: white;
 padding: 8px 18px;
 border-radius: 24px;
 font-size: 13px;
 font-weight: 600;
 backdrop-filter: blur(8px);
 display: flex;
 align-items: center;
 gap: 6px;
}

/* ASI CREDENTIAL STRIP */
.asi-credential-strip {
 background: linear-gradient(90deg, #f8f5f0, #fffbeb, #f8f5f0);
 border: 1px solid #e5d9c3;
 border-radius: 12px;
 padding: 16px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.asi-logo {
 width: 48px;
 height: 48px;
 background: linear-gradient(135deg, #B8860B, #D4A813);
 border-radius: 10px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
 color: white;
 flex-shrink: 0;
 box-shadow: 0 4px 12px rgba(184, 134, 11, 0.25);
}

.asi-text {
 flex: 1;
}

.asi-text .label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1px;
 color: #92400e;
 font-weight: 700;
}

.asi-text .title {
 font-size: 15px;
 color: #78350f;
 font-weight: 600;
 margin-top: 2px;
}

/* TABLE OF CONTENTS */
.toc-box {
 background: #fdf2f4;
 border: 1px solid #e5e7eb;
 border-radius: 16px;
 padding: 24px;
 margin-bottom: 40px;
}

.toc-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #722F37;
 font-weight: 700;
 margin-bottom: 16px;
 display: block;
}

.toc-list {
 list-style: none;
 display: grid;
 grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
 gap: 12px;
}

.toc-list li a {
 display: flex;
 align-items: center;
 gap: 10px;
 text-decoration: none;
 color: #374151;
 font-size: 14px;
 font-weight: 500;
 transition: all 0.2s;
}

.toc-list li a:hover {
 color: #722F37;
}

.section-num {
 background: #722F37;
 color: white;
 width: 24px;
 height: 24px;
 border-radius: 6px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
 flex-shrink: 0;
}

/* WELCOME BOX */
.welcome-box {
 background: linear-gradient(135deg, #fefbf3 0%, #f8f5f0 100%);
 padding: 28px;
 margin-bottom: 40px;
 border-radius: 16px;
 border-left: 5px solid #722F37;
 box-shadow: 0 4px 12px rgba(0, 0, 0, 0.04);
}

.welcome-box h3 {
 color: #722F37;
 font-size: 18px;
 font-weight: 700;
 margin-bottom: 12px;
}

/* OBJECTIVES BOX */
.objectives-box {
 background: linear-gradient(135deg, #faf5ff 0%, #f3e8ff 100%);
 border-radius: 16px;
 padding: 28px;
 margin-bottom: 40px;
 border: 1px solid #e9d5ff;
 border-left: 5px solid #722F37;
}

.box-label {
 font-weight: 700;
 color: #722F37;
 text-transform: uppercase;
 letter-spacing: 1px;
 font-size: 12px;
 margin-bottom: 16px;
 display: block;
}

.objectives-box ul {
 list-style: none;
}

.objectives-box li {
 padding: 8px 0 8px 32px;
 position: relative;
 font-size: 16px;
 color: #4c1d95;
}

.objectives-box li::before {
 content: '‚úì';
 position: absolute;
 left: 0;
 color: #722F37;
 font-weight: 700;
}

/* HIGHLIGHT */
.highlight {
 background: #fdf2f4;
 padding: 2px 4px;
 border-radius: 4px;
 font-weight: 600;
 color: #722F37;
}

/* TYPOGRAPHY */
h2 {
 color: #722F37;
 font-size: 28px;
 margin: 56px 0 24px 0;
 font-weight: 800;
 position: relative;
 padding-bottom: 16px;
}

h2::after {
 content: '';
 position: absolute;
 bottom: 0;
 left: 0;
 width: 60px;
 height: 4px;
 background: #B8860B;
 border-radius: 2px;
}

h3 {
 color: #722F37;
 font-size: 22px;
 margin: 36px 0 16px 0;
 font-weight: 700;
}

/* DATA TABLE */
.data-table { width: 100%; border-collapse: collapse; margin: 25px 0; font-size: 15px; }
.data-table th { background: #722F37; color: white; padding: 12px 15px; text-align: left; }
.data-table td { padding: 12px 15px; border-bottom: 1px solid #e5e7eb; }
.data-table tr:nth-child(even) { background: #f9fafb; }

/* CASE STUDY */
.case-study {
 background: white;
 border-radius: 20px;
 margin: 40px 0;
 border: 1px solid #e5e7eb;
 border-left: 5px solid #722F37;
 box-shadow: 0 8px 30px rgba(0, 0, 0, 0.06);
 overflow: hidden;
}

.case-study-header {
 background: #722F37;
 padding: 20px 28px;
 color: white;
}

.case-study-content {
 padding: 28px;
}

/* COACH TIP BOX */
.coach-tip {
 background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%);
 border: 1px solid #fde047;
 border-radius: 16px;
 padding: 24px 28px;
 margin: 32px 0;
 position: relative;
}

.coach-tip .tip-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #a16207;
 font-weight: 700;
 margin-bottom: 8px;
 display: block;
}

/* CHECK UNDERSTANDING */
.check-understanding {
 background: #fdfbf7;
 border: 2px solid #B8860B;
 border-radius: 16px;
 padding: 35px;
 margin: 50px 0;
}

.check-understanding .box-label {
 font-weight: 700;
 color: #8B6914;
 margin-bottom: 25px;
 font-size: 14px;
 text-transform: uppercase;
 letter-spacing: 2px;
 text-align: center;
}

.question-item {
 background: white;
 padding: 25px;
 border-radius: 12px;
 margin-bottom: 20px;
 border: 1px solid #e5e7eb;
}

.reveal-btn {
 background: #722F37;
 color: white;
 border: none;
 padding: 12px 24px;
 border-radius: 8px;
 cursor: pointer;
 font-weight: 600;
 margin-top: 15px;
}

.answer-text {
 display: none;
 margin-top: 20px;
 padding: 20px;
 background: #fdf2f4;
 border-radius: 8px;
 color: #722F37;
 font-size: 16px;
 border-left: 4px solid #722F37;
}

/* TAKEAWAYS BOX */
.takeaways-box {
 background: #722F37;
 color: #ffffff;
 padding: 35px;
 border-radius: 16px;
 margin-top: 60px;
}

.takeaways-box .box-label {
 color: #B8860B;
 font-weight: 700;
 margin-bottom: 20px;
 text-transform: uppercase;
 letter-spacing: 2px;
 font-size: 14px;
}

.takeaways-box ul {
 margin: 0;
 padding-left: 20px;
}

.takeaways-box li {
 margin-bottom: 12px;
 color: #ffffff;
}

/* REFERENCES BOX */
.references-box {
 background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
 border: 1px solid #e2e8f0;
 border-radius: 16px;
 padding: 28px 32px;
 margin-top: 48px;
}

.references-box .box-label {
 color: #64748b;
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 font-weight: 700;
 margin-bottom: 16px;
}

.references-box ol {
 padding-left: 20px;
}

.references-box li {
 font-size: 14px;
 color: #475569;
 margin-bottom: 8px;
}

.module-connection {
 background: #f0f9ff;
 border: 1px solid #7dd3fc;
 border-radius: 16px;
 padding: 20px 24px;
 margin-bottom: 32px;
}
 </style>
</head>
<body>

<div class="lesson-wrapper">
 <!-- Module Header Card -->
 <div class="module-header-card">
 <span class="module-label">Module 18: L2: Integration & Synthesis</span>
 <h1 class="lesson-title">Advanced Profiling: Lab Synthesis & Bio-Marker Integration</h1>
 <div class="lesson-meta">
 <span class="meta-badge">‚è±Ô∏è 14 min read</span>
 <span class="meta-badge">üí° Lesson 2 of 8</span>
 </div>
 </div>

 <!-- ASI Credential Strip -->
 <div class="asi-credential-strip">
 <div class="asi-logo">A</div>
 <div class="asi-text">
 <div class="label">Credential Verification</div>
 <div class="title">AccrediPro Standards Institute (ASI) Certified Content</div>
 </div>
 </div>

 <!-- Table of Contents -->
 <nav class="toc-box">
 <span class="toc-label">In This Lesson</span>
 <ul class="toc-list">
 <li><a href="#beyond-fsh"><span class="section-num">01</span>Beyond FSH: The LH Ratio</a></li>
 <li><a href="#metabolic-vms"><span class="section-num">02</span>Metabolic Profiling & VMS</a></li>
 <li><a href="#functional-synthesis"><span class="section-num">03</span>DUTCH & GI-Map Integration</a></li>
 <li><a href="#correlation-matrix"><span class="section-num">04</span>The Symptom-Lab Correlation</a></li>
 <li><a href="#genomics"><span class="section-num">05</span>Genetic Considerations (COMT/MTHFR)</a></li>
 </ul>
 </nav>

 <!-- Module Connection -->
 <div class="module-connection">
 <p>In the previous lesson, we explored the interconnectivity of the <strong>P.H.A.S.E. Framework‚Ñ¢</strong>. Now, we move into the technical "detective work" of the <strong>Profile</strong> pillar, learning how to synthesize complex biomarkers to create a truly bio-individual roadmap for your clients.</p>
 </div>

 <!-- Welcome Box -->
 <div class="welcome-box">
 <h3>Welcome, Practitioner</h3>
 <p>One of the most common frustrations for women in midlife is hearing, <em>"Your labs are normal,"</em> while they feel anything but. As an AccrediPro Specialist, your value lies in your ability to look <strong>between the lines</strong>. This lesson will teach you how to synthesize standard serum markers with functional data to uncover the "why" behind the symptoms.</p>
 </div>

 <!-- Learning Objectives -->
 <div class="objectives-box">
 <span class="box-label">Learning Objectives</span>
 <ul>
 <li>Interpret the LH/FSH ratio to identify late-stage perimenopause fluctuations.</li>
 <li>Calculate HOMA-IR to predict and manage vasomotor symptom (VMS) severity.</li>
 <li>Synthesize GI-Map and DUTCH results to address estrogen detoxification.</li>
 <li>Apply the Symptom-Lab Correlation matrix to resolve clinical discrepancies.</li>
 <li>Integrate COMT and MTHFR genetic data into personalized hormone protocols.</li>
 </ul>
 </div>

 <h2 id="beyond-fsh">Beyond FSH: Interpreting Pituitary-Ovarian Dynamics</h2>
 <p>In conventional medicine, <strong>Follicle Stimulating Hormone (FSH)</strong> is often used as a binary switch: if it's over 30 IU/L, a woman is "in menopause." However, in the 2-10 years of perimenopause, FSH can fluctuate wildly from month to month. To provide expert-level care, we must look at the <span class="highlight">LH/FSH ratio</span>.</p>

 <p>In a healthy cycling woman, LH and FSH typically maintain a roughly 1:1 ratio during the follicular phase. As the ovaries become less responsive to pituitary signaling (ovarian insufficiency), the pituitary pumps out <em>more</em> FSH to "scream" at the ovaries to produce eggs. By the time FSH is consistently elevated, the transition is well underway.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip</span>
 <p>üí° If a client presents with "normal" FSH but classic perimenopause symptoms, check the LH. A rising FSH relative to LH (even within the "normal" range) often signals the beginning of the perimenopausal climb before the clinical 30 IU/L threshold is reached.</p>
 </div>

 <h2 id="metabolic-vms">Metabolic Profiling: HOMA-IR and Vasomotor Symptoms</h2>
 <p>One of the most significant breakthroughs in menopause research is the link between <strong>insulin resistance</strong> and the severity of hot flashes and night sweats (VMS). A 2023 meta-analysis confirmed that women with higher fasting insulin levels have a <strong>33% higher risk</strong> of frequent or severe VMS.</p>

 <p>We utilize the <strong>HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)</strong> to profile this risk. You can calculate this using standard bloodwork (Fasting Glucose and Fasting Insulin):</p>

 <p style="text-align: center; font-weight: bold; padding: 20px; background: #f9fafb; border-radius: 8px; margin: 20px 0;">
 (Fasting Glucose [mg/dL] √ó Fasting Insulin [¬µIU/mL]) / 405 = HOMA-IR
 </p>

 <table class="data-table">
 <thead>
 <tr>
 <th>Marker</th>
 <th>Conventional Range</th>
 <th>Optimal (PHASE‚Ñ¢) Range</th>
 <th>Clinical Significance</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td>Fasting Insulin</td>
 <td>2.0 - 24.9 ¬µIU/mL</td>
 <td><strong>2.0 - 5.0 ¬µIU/mL</strong></td>
 <td>Predictor of VMS and weight gain.</td>
 </tr>
 <tr>
 <td>HOMA-IR</td>
 <td>< 2.5</td>
 <td><strong>< 1.5</strong></td>
 <td>Marker of systemic metabolic stability.</td>
 </tr>
 <tr>
 <td>HbA1c</td>
 <td>< 5.7%</td>
 <td><strong>5.0 - 5.3%</strong></td>
 <td>Long-term glucose control and glycation risk.</td>
 </tr>
 </tbody>
 </table>

 <div class="case-study">
 <div class="case-study-header">
 <strong>Case Study: The "Mystery" Hot Flashes</strong>
 </div>
 <div class="case-study-content">
 <p><strong>Client:</strong> Susan, 51, Nurse Practitioner. <br><strong>Symptoms:</strong> Severe night sweats, waking 4x per night, "brain fog." <br><strong>Initial Labs:</strong> FSH was 45 (Menopausal). She was on HRT (Estradiol patch), but symptoms persisted. <br><strong>The Synthesis:</strong> Her Fasting Insulin was 18 ¬µIU/mL (HOMA-IR: 4.2). <br><strong>Outcome:</strong> By addressing insulin sensitivity through the <strong>Harmonize</strong> pillar (low carb, strength training), her night sweats reduced by 80% within 3 weeks, despite no change to her HRT dose.</p>
 </div>
 </div>

 <h2 id="functional-synthesis">Integrating Functional Testing: DUTCH & GI-Map</h2>
 <p>Serum tests (blood) tell us what is <em>circulating</em>. Functional tests tell us how the body is <em>processing</em> those hormones. To fully <strong>Profile</strong> a client, we must integrate these two data sets.</p>

 <h3>The Estrobolome Connection</h3>
 <p>If a client has "Estrogen Dominance" symptoms (heavy periods, breast tenderness) but her serum Estradiol is low, the problem is often in the gut. The <strong>GI-Map</strong> test looks for <strong>Beta-glucuronidase</strong>, an enzyme produced by certain gut bacteria that "un-couples" estrogen that was supposed to be excreted, sending it back into circulation.</p>

 <ul>
 <li><strong>High Beta-glucuronidase:</strong> Indicates the client is recycling estrogen.</li>
 <li><strong>Synthesis:</strong> Combine this with the <strong>DUTCH</strong> test's Phase 2 Methylation marker to see if she can safely neutralize that recycled estrogen.</li>
 </ul>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip</span>
 <p>üí° Practitioners who can interpret the interplay between the gut (GI-Map) and hormones (DUTCH) often command fees of <strong>$1,500 - $3,000</strong> for comprehensive 3-month packages. This is where your specialist status translates into financial freedom.</p>
 </div>

 <h2 id="correlation-matrix">The Symptom-Lab Correlation Matrix</h2>
 <p>Discrepancies between labs and symptoms are not "errors"‚Äîthey are data points. Use the following matrix to guide your synthesis:</p>

 <table class="data-table">
 <thead>
 <tr>
 <th>Symptom Report</th>
 <th>Lab Result</th>
 <th>Likely Synthesis</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td>Extreme Fatigue</td>
 <td>Normal Thyroid (TSH)</td>
 <td>Check <strong>Free T3</strong> and <strong>Reverse T3</strong>; potential HPA-Axis (Cortisol) dysfunction.</td>
 </tr>
 <tr>
 <td>Anxiety / Insomnia</td>
 <td>Normal Progesterone</td>
 <td>Check <strong>Pregnanediol</strong> (DUTCH) for low GABA-ergic metabolites.</td>
 </tr>
 <tr>
 <td>Weight Loss Resistance</td>
 <td>Normal Glucose</td>
 <td>Check <strong>Fasting Insulin</strong>; likely high HOMA-IR (Hidden Insulin Resistance).</td>
 </tr>
 </tbody>
 </table>

 <h2 id="genomics">Genetic Considerations: COMT and MTHFR</h2>
 <p>Epigenetics plays a massive role in how a woman navigates menopause. We focus on two primary variations during the <strong>Profile</strong> stage:</p>

 <p><strong>1. COMT (Catechol-O-Methyltransferase):</strong> This enzyme is responsible for the "Phase 2" detoxification of estrogens. If a client has a "Slow COMT" variation, she may struggle to clear estrogen, leading to increased risk of mood swings and estrogen-sensitive tissue growth. <br><em>Intervention:</em> Support with magnesium and methyl donors.</p>

 <p><strong>2. MTHFR (Methylenetetrahydrofolate Reductase):</strong> This affects the folate cycle and methylation. Poor methylation can lead to high homocysteine (cardiovascular risk) and poor hormone clearance. <br><em>Intervention:</em> Utilize methylated B-vitamins (5-MTHF) rather than synthetic folic acid.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip</span>
 <p>üí° Don't let genetics intimidate you. Treat genetics as the "loaded gun" and lifestyle (the other PHASE pillars) as the "trigger." We use genetic data to refine the protocol, not to diagnose disease.</p>
 </div>

 <div class="check-understanding">
 <p class="box-label">Check Your Understanding</p>
 <div class="question-item">
 <p class="question-text"><strong>1. Why is the LH/FSH ratio often more useful than a single FSH reading in perimenopause?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans1')">Reveal Answer</button>
 <div id="ans1" class="answer-text">FSH fluctuates wildly in perimenopause. The ratio (and the rise of FSH relative to LH) provides a more accurate picture of the pituitary's attempt to stimulate non-responsive ovaries before the final "menopause" threshold is reached.</div>
 </div>
 <div class="question-item">
 <p class="question-text"><strong>2. A client has severe hot flashes and a HOMA-IR of 3.5. What is the primary priority?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans2')">Reveal Answer</button>
 <div id="ans2" class="answer-text">Improving insulin sensitivity. High insulin is a known driver of VMS severity. Addressing blood sugar stabilization (Harmonize pillar) will likely reduce her symptoms more effectively than hormone therapy alone.</div>
 </div>
 <div class="question-item">
 <p class="question-text"><strong>3. Which enzyme, if elevated on a GI-Map, suggests estrogen is being recycled in the gut?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans3')">Reveal Answer</button>
 <div id="ans3" class="answer-text">Beta-glucuronidase. This enzyme deconjugates estrogen, allowing it to be reabsorbed into the bloodstream rather than excreted.</div>
 </div>
 <div class="question-item">
 <p class="question-text"><strong>4. How does a "Slow COMT" genetic variation impact hormone management?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans4')">Reveal Answer</button>
 <div id="ans4" class="answer-text">It slows down the methylation (Phase 2) of estrogen, potentially leading to a buildup of estrogen metabolites and increased symptoms of estrogen dominance, even if serum levels look normal.</div>
 </div>
 </div>

 <div class="takeaways-box">
 <p class="box-label">Key Takeaways</p>
 <ul>
 <li><strong>Look Beyond "Normal":</strong> Functional ranges are narrower than conventional ranges; use HOMA-IR to find hidden metabolic dysfunction.</li>
 <li><strong>Synthesize, Don't Just Read:</strong> Connect gut health (Beta-glucuronidase) to hormone symptoms to find the root of estrogen dominance.</li>
 <li><strong>Metabolism Drives Symptoms:</strong> Insulin resistance is a primary (and often overlooked) driver of hot flash severity.</li>
 <li><strong>Personalize with Genomics:</strong> Use COMT and MTHFR status to fine-tune nutrient support for detoxification and cardiovascular protection.</li>
 </ul>
 </div>

 <div class="references-box">
 <p class="box-label">References & Further Reading</p>
 <ol>
 <li>Thurston, R. C., et al. (2023). "Insulin Resistance and Vasomotor Symptoms in Women During the Menopause Transition." <em>The Journal of Clinical Endocrinology & Metabolism.</em></li>
 <li>Santoro, N., et al. (2021). "The Menopause Transition: Role of the Pituitary-Ovarian Axis." <em>Endocrinology and Metabolism Clinics.</em></li>
 <li>Baker, J. M., et al. (2017). "The Estrobolome: How the Gut Microbiome Regulates Estrogen Levels." <em>Maturitas.</em></li>
 <li>Hall, J. E. (2015). "Endocrinology of the Menopause and Perimenopause." <em>Endocrinology: Adult and Pediatric.</em></li>
 <li>Lobo, R. A. (2017). "Hormone Replacement Therapy and Cardiovascular Disease: The Role of Methylation and COMT." <em>Journal of Steroid Biochemistry.</em></li>
 <li>STRAW+10 Collaborative Group (2012). "Executive Summary of the Stages of Reproductive Aging Workshop + 10." <em>Menopause.</em></li>
 </ol>
 </div>
</div>

<script>
function toggleAnswer(id) {
 const el = document.getElementById(id);
 if (el.style.display === 'block') {
 el.style.display = 'none';
 } else {
 el.style.display = 'block';
 }
}
</script>

</body>
</html>